URL has been copied successfully!
Why did oncologists give a standing ovation to a data presentation on Revolution Medicines’ pancreatic cancer drug, daraxonrasib? Why did biotech stocks perform so badly this week? And are concrete beaches better than normal beaches?
We discuss all that and more on this week’s episode of “The Readout LOUD,” STAT’s biotech podcast.
Please follow us:
